Berndt Modig Sells 2,292 Shares of Pharvaris (NASDAQ:PHVS) Stock

Posted by Stanley Muller on Aug 20th, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CEO Berndt Modig sold 2,292 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the sale, the chief executive officer owned 130,625 shares of the company’s stock, valued at $4,541,831.25. This trade represents a 1.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Berndt Modig also recently made the following trade(s):

On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37.

Pharvaris Price Performance

Shares of PHVS opened at $36.27 on Thursday. The company has a market capitalization of $2.37 billion, a P/E ratio of -11.89 and a beta of -2.31. Pharvaris N.V. has a one year low of $20.65 and a one year high of $36.93. The business’s 50 day simple moving average is $33.97 and its 200-day simple moving average is $30.29.

Pharvaris (NASDAQ:PHVS – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, sell-side analysts anticipate that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Citizens Jmp raised their target price on shares of Pharvaris from $74.00 to $75.00 and gave the company a “market outperform” rating in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada lifted their price target on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Get Our Latest Analysis on Pharvaris

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Quantbot Technologies LP acquired a new position in shares of Pharvaris in the second quarter valued at approximately $41,000. GF Fund Management CO. LTD. acquired a new stake in Pharvaris in the fourth quarter valued at about $35,000. CoreCap Advisors LLC bought a new stake in shares of Pharvaris during the 2nd quarter valued at approximately $93,000. Barclays PLC bought a new stake in Pharvaris during the 4th quarter worth $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris in the 4th quarter valued at approximately $86,000.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

Positive Sentiment: Analyst sentiment remains broadly favorable. HC Wainwright reiterated its Buy rating, while HSBC upgraded Pharvaris to Overweight. RBC raised its price target to $52, and Citizens JMP increased its target to $75. The analyst consensus is “Moderate Buy,” with an average price target of $51.08. Pharvaris analyst coverage
Positive Sentiment: HC Wainwright’s longer-term outlook still assumes a significant improvement in profitability, with its forecast turning positive at $3.09 earnings per share in fiscal 2029. This supports the investment case if Pharvaris’ oral hereditary angioedema treatments successfully advance toward commercialization.
Neutral Sentiment: Pharvaris remains a clinical-stage biotechnology company developing oral therapies for rare bradykinin-driven diseases, led by the investigational PHA121 treatment for hereditary angioedema. The company’s valuation therefore remains highly dependent on clinical and regulatory progress rather than current earnings.
Negative Sentiment: HC Wainwright lowered several earnings forecasts, including fiscal 2026 EPS to a loss of $3.41 from $2.98 and fiscal 2027 EPS to a loss of $3.30 from $2.41. It also reduced estimates for the third and fourth quarters of 2026, fiscal 2028 and fiscal 2029, pointing to greater expected cash burn and a slower path to profitability.
Negative Sentiment: CEO Berndt Modig sold 2,292 shares for approximately $79,693 at an average price of $34.77, reducing his position by 1.72%. He still owns 130,625 shares, making the sale relatively small, but the transaction could modestly weigh on sentiment. Pharvaris CEO stock sale

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.